Developing a Novel Vaccine Against Herpes Simplex Virus Type 1 by mRNA Technology
To develop a novel mRNA vaccine that can be used to prevent and test the herpes simplex virus infection type 1,the coding sequence for HSV1 glycoprotein gD extracellular domain was cloned into the pUC57 vector to obtain a recombinant plasmid by homologous recombination.The HSV1-gDEctodomain gene template was amplified by PCR reaction,and HSV1-gDEctodomain mRNA was obtained by in vitro transcrip-tion reaction.The LNP was used to encapsulate HSV1-gDEctodomain mRNA to obtain mRNA-LNP complex,and the mRNA-LNP complex was injected intramuscularly into the thighs of mice.HSV1-gD antibody titer was determined by ELISA assay.The neutralization antibody titer of HSV1-gD was detected by TCID50 method.The results showed HSV1-gD antibody titer of the immunized mice reached to 1:12800,and the neutralization test showed Vero cells were protected from HSV1 virus infection(green fluorescent GFP and plaques did not appear in the experimental group).All in all,The HSV1 vaccine prepared by mRNA technology can induce specific immune response and has good protective effect.
万方数据
维普
